Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling | BMC Cancer | Full Text

Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling | BMC Cancer | Full Text

Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling

According to GLOBOSCAN, hepatocellular carcinoma (HCC) claimed 782,000 lives in 2018. The tyrosine kinase inhibitor sofafenib is used to treat HCC, but new anticancer agents targeting different pathways are ur...

Authors:Ruey-Shyang Soong, Ravi K. Anchoori, Richard B. S. Roden, Rou-Ling Cho, Yi-Chan Chen, Sheng-Chieh Tseng, Yun-Li Huang, Po-Cheng Liao and Yu-Chiau Shyu

Citation:BMC Cancer 2020 20:386

Content type:Research article

Published on: 6 May 2020

• ViewFull Text
 
• ViewPDF